Brief: Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria
25/02/2026 12:03
Feb 25 (Reuters) - Celldex Therapeutics Inc CLDX.O: CELLDEX COMPLETES ENROLLMENT IN GLOBAL PHASE 3 STUDIES (EMBARQ-CSU1 AND EMBARQ-CSU2) OF BARZOLVOLIMAB IN CHRONIC SPONTANEOUS URTICARIA CELLDEX THERAPEUTICS INC - TOPLINE DATA EXPECTED Q4 2026 CELLDEX THERAPEUTICS INC - BLA SUBMISSION PLANNED FOR 2027 Source text: ID:nGNX4d81LP Further company coverage: CLDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials